TerminatedPhase 1NCT05228015
Oral TEAD Inhibitor Targeting the Hippo Pathway in Subjects with Advanced Solid Tumors
Studying Epithelioid hemangioendothelioma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Ikena Oncology
- Principal Investigator
- Katherine Kim, MD, MDIkena Oncology
- Intervention
- IK-930(drug)
- Enrollment
- 67 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2022 – 2024
Study locations (12)
- The University of Chicago, Chicago, Illinois, United States
- Massachusetts General Hospital, Boston, Massachusetts, United States
- Start Midwest, Grand Rapids, Michigan, United States
- Memorial Sloan Kettering Cancer Center, New York, New York, United States
- University of Pennsylvania Abramson Cancer Center, Philadelphia, Pennsylvania, United States
- Sidney Kimmel Cancer Center at Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States
- Sarah Cannon Research Institute, Nashville, Tennessee, United States
- MD Anderson Cancer Center, Houston, Texas, United States
- Next Oncology, San Antonio, Texas, United States
- Peninsula South Eastern Haematology and Oncology Group (PASO Medical), Frankston, Victoria, Australia
- University Hospitals of Leicester NHS Trust, Leicester, England, United Kingdom
- The Royal Marsden Hospital, London, England, United Kingdom
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05228015 on ClinicalTrials.govOther trials for Epithelioid hemangioendothelioma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07104331SARC046: A Phase II Trial of Nab-Sirolimus in Patients With Progressing or Symptomatic Epithelioid HemangioendotheliomaSarcoma Alliance for Research through Collaboration
- RECRUITINGPHASE1NCT06452160A Study of BGC515 Capsules in Subjects With Advanced Solid TumorsBridGene Biosciences Inc.
- RECRUITINGNCT06408441The Epithelioid Hemangioendothelioma Registry of the European Reference Network on Rare Adult Solid Cancers (EURACAN)Fondazione IRCCS Istituto Nazionale dei Tumori, Milano